New Clinical Trial Aims to Reprogram Cells to Attack a Specific Relapsed Blood Cancer

An upcoming clinical trial at The James aims to reprogram a patient’s immune cells to attack a specific relapsed blood cancer, called multiple myeloma. The idea is to “super-charge” the patient’s immune system so that it responds to the cancer by attacking it – all while offering the patient a drug-free treatment alternative.

Dr. Craig Hofmeister explains more in this week's Toward a Cancer-Free World.